Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices ― United States, 2024
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7336a4
- PMID
- 39264849
- PMCID
- PMC11392226
- OpenAlex
- W4402482889
- Study type
- Guideline
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The guideline addresses a health disparity by offering AI/AN communities an additional vaccine option that maintains early protection against invasive Hib disease while simplifying infant immunization schedules through a combination vaccine. It may improve vaccine uptake and coverage in a high-risk population.
Structured evidence summary
Research question
This guideline addresses the use of Haemophilus influenzae type b (Hib)-containing vaccines among American Indian and Alaska Native infants, who face disproportionately high rates of invasive Hib disease.
Study design
This is a clinical practice guideline issued by CDC's Advisory Committee on Immunization Practices (ACIP) following a June 2024 meeting. The document summarizes evidence considered and provides clinical guidance for Hib vaccination in AI/AN infants and children.
Population and setting
The guideline targets American Indian and Alaska Native infants and children in the United States, a population at increased risk for invasive Hib disease.
Main findings
ACIP now recommends two preferred primary Hib vaccination options for AI/AN infants: monovalent PRP-OMP (2-dose series at 2 and 4 months) or DTaP-IPV-Hib-HepB hexavalent vaccine (3-dose series at 2, 4, and 6 months). Both contain the PRP-OMP Hib component that provides substantial protection after the first dose. For the Hib booster dose, any Hib vaccine except DTaP-IPV-Hib-HepB may be used, with no formulation preferred.
Public-health relevance
The guideline addresses a health disparity by offering AI/AN communities an additional vaccine option that maintains early protection against invasive Hib disease while simplifying infant immunization schedules through a combination vaccine. It may improve vaccine uptake and coverage in a high-risk population.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. The full guideline document is required to assess the strength of the evidence base, voting details, implementation considerations, and contraindications that inform clinical decision-making.
GIDS interpretation
This guideline would be discoverable in GIDS under diseases tagged (Haemophilus influenzae, Hepatitis B, Pertussis, Diphtheria, Tetanus), the United States country filter, and health policy and vaccination topic filters. It reflects U.S. national immunization policy and is relevant to public health programs serving AI/AN populations.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.